Healthcare / BiotechnologyNasdaqCM
$34.30
+0.95 (+2.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-25.3M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$135M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-41.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-27.0M · FCF $-25.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | $1.0M | — | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291000.00 | $634000.00 | $519000.00 | $1.5M | $976000.00 |
| Net Income | $-27.0M | $-27.0M | $-18.5M | $-20.3M | $-19.2M | $-13.0M | $-8.5M | $-13.0M | $-7.9M | $-16.1M | $-16.4M | $-27.5M | $-36.1M | $-48.2M |
| EBITDA | $-31.1M | $-31.1M | $-22.5M | $-25.9M | $-24.8M | — | — | — | — | — | — | — | — | — |
| EPS | -3.20 | -3.20 | -3.20 | -9.71 | -10.40 | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | -2377.6% | — | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% | -7349.1% | -1865.5% | -3671.4% |
| Net Margin | — | — | -1815.3% | — | -949.7% | -324.3% | -132.5% | -471.9% | -63.6% | -5547.8% | -2579.2% | -5298.3% | -2330.6% | -4938.8% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | 0.01 | -0.02 | -0.07 | — | — | -0.10 | -0.18 | — | -0.12 | — | -0.00 | — |
| Current Ratio | 14.36 | 14.36 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-25.3M | $-25.3M | $-25.3M | $-19.1M | $-16.0M | $-19.3M | $-18.0M | $-23.1M | $-26.9M | $-44.6M | $-48.3M | — | — | — |
| Returns | ||||||||||||||
| ROE | -41.9% | -41.9% | -151.3% | 82.1% | 178.4% | 133.3% | 10.6% | 26.6% | 9.5% | 10.7% | 18.0% | 35.3% | 7.2% | 15.9% |
| Valuation | ||||||||||||||
| P/B | 4.48 | 4.48 | 6.94 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | — | — | -37.6% | 132.1% | -77.8% | 4172.9% | -54.1% | 22.2% | -66.5% | 58.7% | — |
| EPS Growth | 0.0% | 0.0% | 67.0% | 6.6% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+115.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.20 → -3.20
Residual
+115.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.